Sector News

Merck appoints Udit Batra to head combined life science business

April 14, 2015
Life sciences
Merck has appointed Udit Batra, currently Chief Executive Officer and President, Merck Millipore, to lead the combined life science business of Merck Millipore and Sigma-Aldrich once the acquisition of Sigma-Aldrich has been successfully completed.
 
The planned $17 billion transaction remains subject to customary closing conditions and regulatory approvals, which the company expects to have completed in mid-2015. Until then, Merck Millipore and Sigma-Aldrich will continue to operate as separate companies with Udit Batra and Rakesh Sachdev, President and Chief Executive Officer, Sigma-Aldrich, running both organisations independently. Rakesh Sachdev will serve in an advisory capacity, as needed, to ensure a smooth transition.
 
Udit Batra, 44, has served as the Chief Executive Officer and President, Merck’s life science business Merck Millipore since March 2014. He joined Merck in 2011 to head the Group’s Consumer Health business. Prior to that, Udit Batra worked at Novartis Vaccines and Diagnostics, where he was head of global public health and market access. He served in a range of executive management positions at Novartis, including global Head of Corporate Strategy and Country President for the Pharma Business in Australia.
 
Karl-Ludwig Kley, Chairman of the Executive Board of Merck, said, “Udit is a proven leader who has demonstrated his ability to work successfully with his leadership team to guide large organisations, drive performance and deliver to our customers. I also want to express my gratitude to the Sigma-Aldrich employees for building the organisation into a leading global life science tools company and to Rakesh, personally, for providing excellent leadership to the Sigma-Aldrich organisation, both culturally and as demonstrated by the company’s strong performance.”
 

comments closed

Related News

July 3, 2022

Novo Nordisk joins with nursing group to highlight correlation between Type 2 diabetes and cardio risk

Life sciences

Despite atherosclerotic cardiovascular disease (ASCVD) being the leading cause of death for people with Type 2 diabetes, half of those people have no idea of this risk. Novo Nordisk has teamed up with the Preventive Cardiovascular Nurses Association (PCNA) for “Making the Connection,” a program to help increase understanding of the link between the two diseases.

July 3, 2022

First treatment for ‘broken heart syndrome’ trialled

Life sciences

The first ever treatment for broken heart syndrome – also known as Takotsubo cardiomyopathy – is to be trialled by researchers at the University of Aberdeen. Scientists will trial a programme of exercise conditioning and psychological therapy for people who have been diagnosed with the condition following a £300,000 grant from the British Heart Foundation.

July 3, 2022

Nestlé acquiring The Better Health Company in market expansion deal

Life sciences

Nestlé Health Science is set to acquire The Better Health Company (TBHC), as part of its goals to grow global market share while spurring innovation across the nutrition industry. The acquisition includes the GO Healthy brand with its vitamins and supplements, Egmont, the Manuka honey brand and New Zealand Health Manufacturing, an Auckland-based manufacturing facility for vitamins minerals and supplements.